YOLFTbeta
11

Chorokbaem Healthcare Co Ltd

118000 · KO · Healthcare / Drug Manufacturers - General

831.00KRW+5.00 (+0.61%)

Price History

Full chart

Market Stats

Previous Close826.00
Open850.00
Day Range805.00 – 850.00
52-Week Range333.00 – 3,780.00
Volume35.61K
Market Cap26.79B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.59
50-Day Avg1,309.88
200-Day Avg2,055.55

About

METACARE CO., Ltd. distributes pharmaceuticals and medical devices in South Korea. The company sells orthopedic medical devices and consumables; and provides pharmaceutical integration and professional logistics services. It is involved in investment advisory. The company was formerly known as SMEDI Co., Ltd. and changed its name to METACARE CO., Ltd. in August 2024. METACARE CO., Ltd. was founded in 2009 and is headquartered in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMs. Soo-Kyung Kim
  • Employees30
  • HeadquartersNo. 202, 156 Byeongjeomjungang-ro, Hwaseong-si, South Korea, Korea
  • Websitehttps://www.meta-care.co.kr

Leadership

  • Ms. Soo-Kyung KimChairman and Chief Executive Officer · b. 1949

Financials

Income Statement

Currency: KRW2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue12.47B11.76B11.45B11.23B36.88B34.47B56.16B26.90B18.61B19.10B17.26B20.21B32.82B
Growth (%)--5.64%-2.65%-1.90%+228.33%-6.53%+62.90%-52.10%-30.80%+2.61%-9.64%+17.10%+62.42%
Cost of Revenue9.38B8.38B10.68B11.89B32.97B32.51B51.85B24.43B13.52B12.58B10.73B12.54B22.82B
Gross Profit2.31B2.93B768.13M-660.41M3.91B1.96B4.30B2.46B5.10B6.52B6.53B7.67B10.00B
Gross Margin18.56%24.88%6.71%-5.88%10.61%5.69%7.66%9.16%27.38%34.12%37.83%37.97%30.48%
Operating Expense7.23B8.99B8.40B5.09B8.51B8.59B4.38B4.62B6.88B6.76B5.52B6.17B8.68B
Operating Income-4.92B-6.06B-7.63B-5.75B-4.59B-6.63B-82.00M-2.16B-1.79B-240.47M1.01B1.50B1.32B
Operating Margin-39.47%-51.54%-66.65%-51.17%-12.46%-19.23%-0.15%-8.01%-9.59%-1.26%5.83%7.45%4.04%
EBITDA-----3.42B-9.52B1.77B16.26B16.64B-42.05B3.16B5.30B5.55B
EBITDA Margin-----9.27%-27.61%3.15%60.47%89.42%-220.16%18.30%26.24%16.90%
Net Income-4.56B-8.85B-7.59B-8.62B-2.91B-12.04B-4.80B11.25B7.74B-49.55B-14.54B8.50B498.24M
Net Income Margin-36.60%-75.21%-66.32%-76.75%-7.89%-34.93%-8.55%41.84%41.58%-259.47%-84.26%42.05%1.52%
R&D157.26M371.71M228.37M192.85M281.07M108.94M17.35M---1.18B--
R&D as % of Total Revenue1.26%3.16%1.99%1.72%0.76%0.32%0.03%---6.85%--
Interest Expense000001.49B5.34B3.70B7.63B5.55B2.97B399.25M2.45B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%4.32%9.51%13.74%41.01%29.04%17.19%1.98%7.46%

Balance Sheet

Currency: KRW2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets21.97B19.67B16.41B28.84B36.74B61.44B69.80B138.29B176.30B189.86B155.30B157.82B197.96B
Total Liabilities5.92B11.36B10.22B15.41B18.03B42.93B33.87B62.17B56.90B60.28B17.60B41.02B76.98B
Total Equity15.70B8.16B6.19B13.44B18.52B18.39B35.82B76.04B119.40B99.24B105.91B116.80B119.42B
Cash216.25M836.49M275.35M300.41M1.40B35.21B18.23B14.71B59.24B28.47B20.08B30.06B1.59B
Net Debt----7.36B-4.60B10.43B-5.27B-4.71B57.59B

Cash Flow

Currency: KRW2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow258.12M-5.22B-3.56B-4.85B-12.69B-2.71B1.24B3.79B-1.49B-2.53B-12.86B4.48B2.42B
Investing Cash Flow-6.98B393.68M-1.07B-15.32B13.24B-452.83M-29.35B-57.49B11.85B-36.72B---
Financing Cash Flow664.32M5.45B4.07B20.20B540.91M36.97B11.13B50.17B34.17B8.49B---
Capital Expenditure390.33M737.77M1.47B139.99M78.78M118.81M61.70M92.84M26.48M109.28M5.04B2.90B7.34B
Free Cash Flow-----12.79B-2.89B1.18B3.63B-1.52B-2.70B-17.89B1.58B-4.92B
FCF to OCF----100.77%106.76%95.04%95.75%102.01%106.57%139.16%35.24%-203.33%

Earnings

Report DateMar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------------------------------
EPS Actual3176.86-2819.01-2756.25-2501.14-1001.23-8025.23-2713.46-9173.42-1614.68-3226.85-684.24-822.87-722.88-822.04-1088.60-1654.72-1160.71-1132.48-995.07-4915.11-1563.52-1771.01-1567.13-1182.62-656.83-754.42-639.08-2243.17-469.90-981.54-1011.58197.69-702.38-836.69-567.97-2466.30-783.45-680.77-587.23215.33-401.89847.61654.641107.02-595.201954.82-573.01281.38-372.70-1925.63-1267.02-2274.18-139.65342.34-495.65-772.30953.02-120.4630.97-187.49-0.49177.0275.40-216.5224.2923.15
Surprise------------------------------------------------------------------
Timing------------------------------------------------------------------

Key Statistics & Ratios

Market Cap26.79B
Enterprise Value90.80B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.67
Price / Book0.22
Revenue (TTM)39.95B
Gross Profit (TTM)10.74B
EBITDA4.37B
Profit Margin-3.99%
Operating Margin9.09%
Return on Equity-1.42%
Return on Assets0.39%
Shares Outstanding22.05M
Shares Float9.91M
Beta0.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 24, 20260.1:1
  • Feb 13, 20141:10